Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Norzyme after pancreatoduodenectomy
NCT02127021Phase 4Completed
- Sponsor
- Seoul National University Hospital
- Start
- Apr 2014
- Primary completion
- Sep 2017
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in pancreatic exocrine insufficiency (EPI) comparing Norzyme 40000 IU with Placebo (2 arms). Primary endpoint: Change from Baseline in body weight at 3 months. Started Apr 2014; status: completed.
02
Drugs
pancreatin
03
Conditions
pancreatic exocrine insufficiency (EPI)
Beyond the preview
Go deeper on NCT02127021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02127021.